Meeting
2022 ASCO Annual Meeting
Safety and efficacy of mitoxantrone hydrochloride liposome in patients with platinum-refractory or platinum-resistant ovarian cancer: A prospective, multicenter, open-label, single-arm, phase Ib clinical trial.
Authors
Yu Huang
Gynecological Oncology Center, Chongqing University Cancer Hospital, Chongqing, China
Yu Huang , Rong Li , Li Guiling , Yanlin Luo , Zhijun Yang , Ge Lou , Weiwei Ouyang , Rong Xie , Wuxia Luo , Lixin Chen , Qi Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04718376
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5550)
DOI
10.1200/JCO.2022.40.16_suppl.5550
Abstract #
5550
Poster Bd #
429
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2021 ASCO Annual Meeting
Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Marwan Fakih
Poster
2019 ASCO Annual Meeting
Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study.
First Author: Isabelle Laure Ray-Coquard
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.
First Author: Nieves Martinez Lago